Imiquimod enhances anti-lymphoma response in a tumor cell lysate vaccine and inhibits tumor cells growth.

MONGINI, C; DE TORO J; HERSCHLIK L; GRAVISACO MJ; WALDNER C; DI SCIULLO P

Milán

Congreso; 15th International Congress of Immunolog; 2013

IUIS International Union of Immunological Societie

Our aim was to study the immunomodulating and proapoptotic properties of the TLR7 agonist Imiquimod to be used as adjuvant in a tumor vaccine. Imiquimod showed an antiproliferative effect on LBC T-cell lymphoma in vitro at 48 and 72 h with doses between 0.5 and 200 μg/ml, inducing apoptosis in a dose dependent manner. BALB/c mice inoculated intraperitoneally twice with LBC cells lysates with or without 100 μg/mouse of Imiquimod and challenged one week later with LBC cells intraperitoneally, showed a significant increase in survival compared to un-immunized controls (LBC-lysate